IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% Study concluded that most non-surgical patients with early-stage breast cancer accepted cryoablation when the treatment was offered and that cryoablation is a safe, effective alternative to surgery and well-tolerated as an out-patient procedure
Bought PLSE at $1.90 in November of 2022 when it was a 50 million market cap now over a Billion market cap. Timing is everything. ICCM has a immeasurable upside in IceCure FDA Panel Meeting November 7th for Breast Cancer Indication half a dozen independent studies completed now with 5 year follow up Data will get green lighted. Also works well in Lung Kidney and Liver indications. Billionaire owns about 50% of the shares who founded Tencent. $ICCM
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.